News & Updates
Filter by Specialty:
Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
In the treatment of adults with uncontrolled focal seizures, the long-term, open-label use of cenobamate appears to produce high rates of sustained 100-percent and ≥90-percent seizure reduction, with parallel decreases in concomitant antiseizure medication (ASM) doses, according to two separate post hoc analyses of a phase III C021 trial.
Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
12 Nov 2021
Metabolic dysfunction-associated fatty liver disease ups risk of severe COVID-19
Metabolic dysfunction-associated fatty liver disease (MAFLD) can escalate the incidence of severe COVID-19, but no association between MAFLD and COVID-19 death has been confirmed, suggest the results of a meta-analysis.
Metabolic dysfunction-associated fatty liver disease ups risk of severe COVID-19
12 Nov 2021
Maintenance with ABC/3TC + RPV sustains virological suppression in HIV-1
Switching to abacavir/lamivudine plus rilpivirine (ABC/3TC + RPV) for maintenance therapy is a safe and effective option for patients with virologically suppressed HIV-1, according to a recent Singapore study.
